Get started
Author

Ben Mulhearn

Observed names: B Mulhearn, B. Mulhearn, Mulhearn, Ben
Observed institutions: Royal National Hospital for Rheumatic Diseases, University Hospitals of Morecambe Bay NHS Foundation Trust, University of Colorado Boulder, Royal Lancaster Infirmary, Manchester Academic Health Science Centre, Yeovil District Hospital NHS Foundation Trust, Royal United Hospital, University of Manchester, Manchester University NHS Foundation Trust, Istanbul University-Cerrahpaşa, The Christie NHS Foundation Trust, Yeovil District Hospital, NIHR Manchester Biomedical Research Centre, Royal United Hospital Bath NHS Trust, Arthritis Research UK, Manchester Collaborative Centre for Inflammation Research, University of Bath, Istanbul University, Medical Research Council
ORCID: 0000-0003-2119-2155
Observed ORCID: 0000-0003-2119-2155
OpenAlex ID: A5026928779
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 2,153
PDF
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 562
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 508
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 393
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 354
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 302
Indications for IVIG in rheumatic diseases
2014 · B. Mulhearn, I. N. Bruce · Rheumatology · 80
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 41
PDF
Autoantibodies in connective tissue disease
2019 · Ben Mulhearn, Sarah L. Tansley, et al. · Best Practice & Research Clinical Rheumatology · 35
Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis
2019 · Ben Mulhearn, Anne Barton, et al. · Journal of Personalized Medicine · 24
PDF
A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing
2022 · Ben Mulhearn, Danyang Li, et al. · Frontiers in Immunology · 23
PDF
Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England
2023 · Vanessa Quick, Mahdi Abusalameh, et al. · Rheumatology · 20
PDF
The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population
2022 · Aravinthan Loganathan, Fionnuala McMorrow, et al. · Frontiers in Immunology · 17
Automated clustering reveals CD4+ T cell subset imbalances in rheumatoid arthritis
2023 · B Mulhearn, L Marshall, et al. · Frontiers in Immunology · 14
Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
2021 · Shaney L Barratt, Havra H Adamali, et al. · BMJ Open Respiratory Research · 13
PDF
What rheumatologists need to know about innate lymphocytes
2016 · Mark A. Exley, George C. Tsokos, et al. · Nature Reviews Rheumatology · 13
PDF
Incidence of giant cell arteritis is associated with COVID-19 prevalence: A population-level retrospective study
2023 · Ben Mulhearn, Jessica Ellis, et al. · Heliyon · 10
PDF
Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry‘
2021 · Ben Mulhearn · Annals of the Rheumatic Diseases · 5
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 3
PDF
Coming to a hard stop? Effect of tapered tocilizumab after weekly tocilizumab cessation for GCA: a multicentre evaluation
2025 · Vanessa Quick, Stephen Sah, et al. · Rheumatology · 3
PDF
The Development and Validation of a Novel Training Infographic for the Physician Global Visual Analog Scale in Psoriatic Arthritis
2024 · Shannon Gunawardana, Philip S. Helliwell, et al. · The Journal of Rheumatology · 3
PDF
Rituximab fails to treat giant cell arteritis in a patient with ACPA-positive rheumatoid arthritis
2021 · Ben Mulhearn, Edwin Cooper, et al. · Rheumatology Advances in Practice · 3
PDF
Pos0726 Rituximab Versus Cyclophosphamide for Anca- Associated Vasculitis: a Cost Analysis
2023 · E. Amor, B. Mulhearn, et al. · Annals of the Rheumatic Diseases · 2
PDF
E070 How well is the mental health of rheumatoid arthritis patients assessed in the routine rheumatology clinic?
2023 · Hannah Cooney, Jessica Ellis, et al. · Rheumatology · 1
PDF
P290 Baseline monocyte count may help make a diagnosis of giant cell arteritis: results of routinely collected audit data from two centres
2022 · Ben Mulhearn, Jessica Ellis, et al. · Rheumatology · 1
PDF
Works count: 49
Citation count: 4,584
H-index: 14
I10-index: 17
Year
Topic
Type